Learn
Delve into dermatology diseases with new approaches from conventional to complementary care.
Topics
Explore a broad spectrum of dermatological conditions and topics to enhance your practice.
Training Programs
Expert led instruction for every level of patient care.
Log in to see enrolled program content.
Conferences
Gain practical insights and meet new colleagues.
Hover over a conference to view recordings.
Join Us
The largest integrative dermatology community.
Biosimilars: Where Are We Now?
Course Overview
Preview what you'll learn in this program
What You'll Learn
Biosimilar medications are "highly similar" to an already FDA-approved biological product. Several biosimilars have already been approved in the US for the treatment of psoriasis, with more sure to follow in the near future. The FDA is responsible for and has a process for ensuring the safety and efficacy of bio similars.
Faculty
Editors
Accreditation Information
Biosimilar medications are "highly similar" to an already FDA-approved biological product. Several biosimilars have already been approved in the US for the treatment of psoriasis, with more sure to follow in the near future. The FDA is responsible for and has a process for ensuring the safety and efficacy of bio similars.
✨ Ready to Begin Your Journey? ✨
Enroll now to start the course and unlock all learning materials
Biosimilars: Where Are We Now?
Complete the previous section to unlock this lesson
Biosimilars: Where Are We Now? Module
Complete the previous section to unlock this lesson
Course Discussion
Join the conversation with fellow learners
Also Recommended
Extracutaneous Comorbidities of Psoriasis: Joint, Cardiovascular, Metabolic, and Psychological Impact
Assessing Metabolic Syndrome in a Patient with Psoriasis
How to Manage a Patient with Psoriasiform Dermatitis following Immunotherapy Treatment
Case-Based Learning: Difficult Psoriasis – Challenges from the Clinic
